Cambiar Investors Has Upped Orange (ORAN) Stake By $5.44 Million; Shorts at Evoke Pharma (EVOK) Raised By 0.05%

February 13, 2018 - By Marguerite Chambers

Evoke Pharma Incorporated (NASDAQ:EVOK) had an increase of 0.05% in short interest. EVOK’s SI was 1.20 million shares in February as released by FINRA. Its up 0.05% from 1.19 million shares previously. With 60,900 avg volume, 20 days are for Evoke Pharma Incorporated (NASDAQ:EVOK)’s short sellers to cover EVOK’s short positions. The SI to Evoke Pharma Incorporated’s float is 12.39%. The stock increased 1.24% or $0.03 during the last trading session, reaching $2.44. About 4,946 shares traded. Evoke Pharma, Inc. (NASDAQ:EVOK) has declined 51.99% since February 13, 2017 and is downtrending. It has underperformed by 68.69% the S&P500.

Cambiar Investors Llc increased Orange (ORAN) stake by 4.5% reported in 2017Q3 SEC filing. Cambiar Investors Llc acquired 340,141 shares as Orange (ORAN)’s stock rose 11.19%. The Cambiar Investors Llc holds 7.90M shares with $129.68M value, up from 7.56 million last quarter. Orange now has $42.31 billion valuation. The stock decreased 0.91% or $0.1531 during the last trading session, reaching $16.6469. About 25,725 shares traded. Orange S.A. (NYSE:ORAN) has risen 1.61% since February 13, 2017 and is uptrending. It has underperformed by 15.09% the S&P500.

Among 7 analysts covering Orange (NYSE:ORAN), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. Orange had 12 analyst reports since July 21, 2015 according to SRatingsIntel. On Tuesday, January 17 the stock rating was upgraded by HSBC to “Buy”. The stock of Orange S.A. (NYSE:ORAN) earned “Hold” rating by Deutsche Bank on Tuesday, July 21. Raymond James upgraded Orange S.A. (NYSE:ORAN) on Tuesday, July 19 to “Outperform” rating. The rating was upgraded by Credit Suisse to “Outperform” on Tuesday, September 27. As per Wednesday, August 31, the company rating was downgraded by Bank of America. The stock has “Hold” rating by Berenberg on Monday, January 23. As per Monday, June 19, the company rating was downgraded by Berenberg. Berenberg upgraded the stock to “Hold” rating in Friday, December 8 report. The firm has “Hold” rating by Bank of America given on Tuesday, June 13. The company was downgraded on Monday, October 3 by HSBC.

Cambiar Investors Llc decreased Energizer Hldgs Inc New stake by 14,493 shares to 264,650 valued at $12.19 million in 2017Q3. It also reduced American Wtr Wks Co Inc New (NYSE:AWK) stake by 61,066 shares and now owns 465,411 shares. United Cmnty Bks Blairsvle G (NASDAQ:UCBI) was reduced too.

Among 9 analysts covering Evoke Pharma (NASDAQ:EVOK), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. Evoke Pharma had 19 analyst reports since August 20, 2015 according to SRatingsIntel. The stock has “Buy” rating by Rodman & Renshaw on Thursday, January 5. Rodman & Renshaw maintained it with “Neutral” rating and $2.50 target in Friday, December 23 report. The rating was initiated by Brean Capital with “Buy” on Thursday, August 20. On Monday, September 18 the stock rating was maintained by H.C. Wainwright with “Buy”. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, November 29 report. The stock of Evoke Pharma, Inc. (NASDAQ:EVOK) has “Outperform” rating given on Wednesday, March 16 by Northland Capital. The stock has “Buy” rating by H.C. Wainwright on Tuesday, August 15. The company was downgraded on Tuesday, July 19 by Noble Financial. The stock has “Hold” rating by Brean Capital on Monday, July 18. The firm has “Buy” rating by Rodman & Renshaw given on Friday, October 2.

Investors sentiment increased to 4.5 in 2017 Q3. Its up 3.00, from 1.5 in 2017Q2. It is positive, as 2 investors sold Evoke Pharma, Inc. shares while 0 reduced holdings. 4 funds opened positions while 5 raised stakes. 4.20 million shares or 123.21% more from 1.88 million shares in 2017Q2 were reported. State Bank Of Ny Mellon has invested 0% in Evoke Pharma, Inc. (NASDAQ:EVOK). California Pub Employees Retirement invested in 0% or 36,700 shares. Vanguard Group Inc has invested 0% in Evoke Pharma, Inc. (NASDAQ:EVOK). Two Sigma Securities Limited Liability Company owns 0% invested in Evoke Pharma, Inc. (NASDAQ:EVOK) for 11,137 shares. Morgan Stanley owns 5,950 shares. National Bank & Trust Of America Corporation De, North Carolina-based fund reported 10,000 shares. Citigroup Incorporated owns 500 shares. 571,022 were reported by Sphera Funds Mgmt. Commonwealth Equity reported 30,062 shares. Millennium Ltd Liability owns 54,853 shares or 0% of their US portfolio. Knoll Management Limited Partnership owns 225,000 shares. State Treasurer State Of Michigan has invested 0.01% of its portfolio in Evoke Pharma, Inc. (NASDAQ:EVOK). Northern Trust Corporation accumulated 0% or 29,214 shares. United Capital Fincl Advisers Limited Liability Corp holds 15,566 shares. Virtu Fin Limited Liability Company holds 0% or 39,489 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>